Theorem Clinical Research

Global News

Report: CROs an innovation partner in clinical trials

Thursday, October 9, 2014 11:33 AM

“Clinical trials today are more responsive, individualized and effective because it’s written into the DNA of CROs to challenge the status quo,’’ according to a new Association of Clinical Research Organizations (ACRO) report, Clinical Research: A Legacy of Innovation, A Future of Transformed Medicine.

More... »


CSL Behring expands manufacturing capabilities

Thursday, October 9, 2014 11:32 AM

CSL Behring, a King of Prussia, Pa.-based provider of plasma protein therapeutics, has announced a multi-year, $450-million two-site global capacity expansion, the latest in a series of recent production expansions to meet the growing need for therapies used to treat patients with rare and serious medical disorders around the world. 

More... »


CRF Health names Sarah Dixon vice president of human resources

Thursday, October 9, 2014 11:30 AM

CRF Health, a global provider of eCOA solutions for the Life Sciences Industry, has appointed Sarah Dixon the company's vice president of human resources.

More... »

Bristol-Myers Squibb researchers receive a 2014 PhRMA Research and Hope Award

Thursday, October 9, 2014 11:22 AM

Bristol-Myers Squibb scientists have received the 2014 Pharmaceutical Research and Manufacturers of America (PhRMA) Research and Hope Award for Biopharmaceutical Industry Research excellence. This year’s award program honored outstanding individuals and organizations for their commitment and progress in the field of HIV/AIDS research.

More... »

MyCartis launches Evalution, a next generation multiplex biomarker analysis platform

Thursday, October 9, 2014 10:30 AM

MyCartis, a Switzerland and Belgium-based new company dedicated to changing healthcare through personalization originating from Biocartis’ business unit Evalution and Pronota, has launched Evalution, a multiplex biomarker analysis platform for the life sciences research market.

More... »

Bristol-Myers Squibb, Novartis collaborate on NSCLC

Thursday, October 9, 2014 10:00 AM

Bristol-Myers Squibb has established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of combining Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) with three molecularly targeted oncology therapies (Zykadia (ceritinib), INC280 and EGF816) from Novartis. Novartis will conduct two phase I/II studies focused on non-small cell lung cancer (NSCLC).

More... »

Bristol-Myers Squibb, MD Anderson Cancer Center collaborate

Thursday, October 9, 2014 09:30 AM

Bristol-Myers Squibb and the University of Texas MD Anderson Cancer Center have formed a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as potential treatment options for acute and chronic leukemia as well as other hematologic malignancies.

More... »

Formex expands services, adds scientific staff and equipment

Thursday, October 9, 2014 08:27 AM

Formex, a pharmaceutical formulation developer and manufacturer, has expanded both scientific personnel and equipment.

More... »

Survey: Global medtech industry needs to better differentiate products

Wednesday, October 8, 2014 01:53 PM

Despite ongoing commercial challenges in 2013, the global medtech industry's financial performance held steady at the relatively low levels of growth that have become common in recent years. But even as the industry grapples with these market and regulatory pressures, it faces a potential growing challenge—the threat of commoditization, according to new findings outlined in Ernst & Young's annual medical technology report, Pulseof the industry: differentiating differently.

More... »

Teva announces results of strategic review of core specialty therapeutic areas

Wednesday, October 8, 2014 01:49 PM

Teva Pharmaceutical Industries has identified 14 pipeline projects for discontinuation or divestment as part of its strategic review of core therapeutic areas for the company. These projects amount to more than $150 million in R&D costs in 2015 and in excess of $200 million for each of 2016 and 2017.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs